KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Cvs Health (CVS) over the last 17 years, with Q4 2025 value amounting to $135.0 million.

  • Cvs Health's Share-based Compensation fell 145.99% to $135.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $535.0 million, marking a year-over-year decrease of 92.59%. This contributed to the annual value of $535.0 million for FY2025, which is 92.59% down from last year.
  • Cvs Health's Share-based Compensation amounted to $135.0 million in Q4 2025, which was down 145.99% from $138.0 million recorded in Q3 2025.
  • Over the past 5 years, Cvs Health's Share-based Compensation peaked at $204.0 million during Q2 2023, and registered a low of $87.0 million during Q1 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $134.0 million (2024), whereas its average is $129.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 7469.88% in 2021, then tumbled by 3480.39% in 2024.
  • Cvs Health's Share-based Compensation (Quarter) stood at $138.0 million in 2021, then dropped by 23.19% to $106.0 million in 2022, then grew by 19.81% to $127.0 million in 2023, then rose by 7.87% to $137.0 million in 2024, then dropped by 1.46% to $135.0 million in 2025.
  • Its Share-based Compensation stands at $135.0 million for Q4 2025, versus $138.0 million for Q3 2025 and $136.0 million for Q2 2025.